glutathione inhibitor bso DL-Buthionine-sulfoximine Frontiers | Preclinical investigations of
Frontiers Preclinical investigations of the efficacy of the glutaminase inhibitor CB 839 alone and in combinations in chronic lymphocytic leukemia Combined inhibition of de novo glutathione and nucleotide biosynthesis is synthetically lethal in glioblastoma ScienceDirect The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma Blood Cancer Journal Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression ScienceDirect
Pay in 4 interest-free payments of $5.26 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17



